Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/149371
Title: miR-146a targets Fos expression in human cardiac cells
Author: Palomer Tarridas, Francesc Xavier
Capdevila Busquets, Eva
Botteri, Gaia
Davidson, Mercy M.
Rodríguez, Cristina
Martínez González, José
Vidal, Francisco, 1966-
Barroso Fernández, Emma
Chan, Tung O
Feldman, Arthur M.
Vázquez Carrera, Manuel
Keywords: Micro RNAs
Cèl·lules
Cor
MicroRNAs
Cells
Heart
Issue Date: 25-Jun-2015
Publisher: The Company of Biologists
Abstract: miR-146a is a microRNA whose transcript levels are induced in the heart upon activation of NF-kappaB, a transcription factor induced by pro-inflammatory molecules strongly related to the pathogenesis of cardiac disorders. The main goal of this study consisted in studying new roles of miR-146a in cardiac pathological processes caused by the pro-inflammatory cytokine TNF-alpha. Our results demonstrate that miR-146a transcript levels were sharply increased in cardiac ventricular tissue of transgenic mice with specific overexpression of TNF-alpha in the heart, and also in a cardiomyocyte cell line of human origin (AC16) exposed to TNF-alpha. Among all the in silico predicted miR-146a target genes, c-Fos mRNA and protein levels notably decreased after TNF-alpha treatment or miR-146a overexpression. These changes correlated with a diminution in the DNA-binding activity of AP-1, the c-Fos-containing transcription factor complex. Interestingly, AP-1 inhibition was accompanied by a reduction in matrix metalloproteinase (MMP)-9 mRNA levels in human cardiac cells. The specific regulation of this matrix metalloproteinase by miR-146a was further confirmed at the secretion and enzymatic activity levels, as well as after anti-miR-mediated miR-146a inhibition. The results reported here demonstrate that c-Fos is a direct target of miR-146a activity and that c-Fos/AP-1 pathway downregulation by miR-146a has the capacity to inhibit MMP-9 activity. Given that MMP-9 is an AP-1 target gene involved in cardiac remodeling, myocardial dysfunction and progression of heart failure, these findings suggest that miR-146a may be a new and promising therapeutic tool for treating cardiac disorders associated with enhanced inflammation in the heart.
Note: Reproducció del document publicat a: https://doi.org/10.1242/dmm.020768
It is part of: Disease Models & Mechanisms, 2015, vol. 8, num. 9, p. 1081-1091
URI: http://hdl.handle.net/2445/149371
Related resource: https://doi.org/10.1242/dmm.020768
ISSN: 1754-8403
Appears in Collections:Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
Articles publicats en revistes (Institut de Biomedicina (IBUB))

Files in This Item:
File Description SizeFormat 
654607.pdf1.28 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons